Women in the RCT reported an adjusted mean increase of 13.7 points ( 95 % CI 10.2 , 17.1 ) in global QoL at 24 months ( vs. mid-treatment ) , while women treated off-trial had only an adjusted improvement of 7.0 points ( 95 % CI 3.5 , 10.4 ; p = .007 for difference in mean changes ) .